Cargando…
Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
Secondary ovarian tumor [secondary tumor of the ovary (STO)] is not a frequent disease. To date, there is still a lack of standard treatment for STO due to the relative heterogeneity. Liver cancer metastasis to the ovary is extremely rare, with only 17 living cases having been reported so far, makin...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791028/ https://www.ncbi.nlm.nih.gov/pubmed/36578942 http://dx.doi.org/10.3389/fonc.2022.1010158 |
_version_ | 1784859308704399360 |
---|---|
author | Li, Caixia Ye, Wenlei Zhou, Wenni Ye, Zhikang Yang, Weihong Cheng, Zhongping |
author_facet | Li, Caixia Ye, Wenlei Zhou, Wenni Ye, Zhikang Yang, Weihong Cheng, Zhongping |
author_sort | Li, Caixia |
collection | PubMed |
description | Secondary ovarian tumor [secondary tumor of the ovary (STO)] is not a frequent disease. To date, there is still a lack of standard treatment for STO due to the relative heterogeneity. Liver cancer metastasis to the ovary is extremely rare, with only 17 living cases having been reported so far, making it impossible to launch large-scale prospective studies and formulate the standard intervention for patients. We herein report a rare case of STO with liver primary cancer metastasis to the ovary and omentum in a 66-year-old woman. The patient underwent debulking surgery with the removal of the uterus, bilateral fallopian tubes, bilateral ovaries, appendix, and a large part of the omentum majus. Next-generation sequencing was conducted after the operation, identifying BRCA2 mutation. Because strongly refusing chemotherapy, she received olaparib as an experimental therapy. After the administration of surgery and olaparib, the serum value of cancer antigen 125 (CA125) and alpha fetoprotein (AFP) decreased dramatically and basically remained within the normal range. So far, she has achieved nearly 2-year survival and lives a relatively normal life with good quality. |
format | Online Article Text |
id | pubmed-9791028 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97910282022-12-27 Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer Li, Caixia Ye, Wenlei Zhou, Wenni Ye, Zhikang Yang, Weihong Cheng, Zhongping Front Oncol Oncology Secondary ovarian tumor [secondary tumor of the ovary (STO)] is not a frequent disease. To date, there is still a lack of standard treatment for STO due to the relative heterogeneity. Liver cancer metastasis to the ovary is extremely rare, with only 17 living cases having been reported so far, making it impossible to launch large-scale prospective studies and formulate the standard intervention for patients. We herein report a rare case of STO with liver primary cancer metastasis to the ovary and omentum in a 66-year-old woman. The patient underwent debulking surgery with the removal of the uterus, bilateral fallopian tubes, bilateral ovaries, appendix, and a large part of the omentum majus. Next-generation sequencing was conducted after the operation, identifying BRCA2 mutation. Because strongly refusing chemotherapy, she received olaparib as an experimental therapy. After the administration of surgery and olaparib, the serum value of cancer antigen 125 (CA125) and alpha fetoprotein (AFP) decreased dramatically and basically remained within the normal range. So far, she has achieved nearly 2-year survival and lives a relatively normal life with good quality. Frontiers Media S.A. 2022-12-12 /pmc/articles/PMC9791028/ /pubmed/36578942 http://dx.doi.org/10.3389/fonc.2022.1010158 Text en Copyright © 2022 Li, Ye, Zhou, Ye, Yang and Cheng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Li, Caixia Ye, Wenlei Zhou, Wenni Ye, Zhikang Yang, Weihong Cheng, Zhongping Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer |
title | Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer |
title_full | Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer |
title_fullStr | Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer |
title_full_unstemmed | Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer |
title_short | Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer |
title_sort | case report: olaparib as an experimental therapy in a brca2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791028/ https://www.ncbi.nlm.nih.gov/pubmed/36578942 http://dx.doi.org/10.3389/fonc.2022.1010158 |
work_keys_str_mv | AT licaixia casereportolaparibasanexperimentaltherapyinabrca2mutatedpatientwithmetastaticovarianadenocarcinomathatoriginatedfromlivercancer AT yewenlei casereportolaparibasanexperimentaltherapyinabrca2mutatedpatientwithmetastaticovarianadenocarcinomathatoriginatedfromlivercancer AT zhouwenni casereportolaparibasanexperimentaltherapyinabrca2mutatedpatientwithmetastaticovarianadenocarcinomathatoriginatedfromlivercancer AT yezhikang casereportolaparibasanexperimentaltherapyinabrca2mutatedpatientwithmetastaticovarianadenocarcinomathatoriginatedfromlivercancer AT yangweihong casereportolaparibasanexperimentaltherapyinabrca2mutatedpatientwithmetastaticovarianadenocarcinomathatoriginatedfromlivercancer AT chengzhongping casereportolaparibasanexperimentaltherapyinabrca2mutatedpatientwithmetastaticovarianadenocarcinomathatoriginatedfromlivercancer |